ZURA vs. ABOS, INMB, OPT, CGEN, KOD, ELEV, IPHA, ADVM, XFOR, and IPSC
Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Acumen Pharmaceuticals (ABOS), INmune Bio (INMB), Opthea (OPT), Compugen (CGEN), Kodiak Sciences (KOD), Elevation Oncology (ELEV), Innate Pharma (IPHA), Adverum Biotechnologies (ADVM), X4 Pharmaceuticals (XFOR), and Century Therapeutics (IPSC). These companies are all part of the "biological products, except diagnostic" industry.
Zura Bio (NASDAQ:ZURA) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.
In the previous week, Zura Bio had 3 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 8 mentions for Zura Bio and 5 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.26 beat Zura Bio's score of 0.13 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.
Acumen Pharmaceuticals received 8 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 64.29% of users gave Acumen Pharmaceuticals an outperform vote.
61.1% of Zura Bio shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 15.8% of Zura Bio shares are held by insiders. Comparatively, 7.5% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Zura Bio has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
Acumen Pharmaceuticals' return on equity of -23.40% beat Zura Bio's return on equity.
Zura Bio currently has a consensus target price of $18.00, indicating a potential upside of 282.17%. Acumen Pharmaceuticals has a consensus target price of $12.25, indicating a potential upside of 260.29%. Given Zura Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Zura Bio is more favorable than Acumen Pharmaceuticals.
Summary
Acumen Pharmaceuticals beats Zura Bio on 7 of the 13 factors compared between the two stocks.
Get Zura Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zura Bio Competitors List
Related Companies and Tools
